Glimitab-MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, formulated for sustained release to provide effective glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, reducing postprandial hyperglycemia. The combined mechanism addresses multiple pathophysiological defects of type 2 diabetes, offering improved glycemic control compared to monotherapy. Glimitab-MV 2 is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. The sustained-release formulation ensures gradual drug release, minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. This combination should be used under medical supervision with regular monitoring of blood glucose levels, renal function, and liver enzymes. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. Proper adherence to prescribed dosage and lifestyle modifications is essential for optimal therapeutic outcomes.